A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial

Kazumoto Shibuya, Sonoko Misawa, Hideki Kimura, Yu Ichi Noto, Yasunori Sato, Yukari Sekiguchi, Yuta Iwai, Satsuki Mitsuma, Minako Beppu, Keisuke Watanabe, Yumi Fujimaki, Yukiko Tsuji, Toshio Shimizu, Toshiki Mizuno, Masanori Nakagawa, Kyoko Sawaguchi, Hideki Hanaoka, Satoshi Kuwabara

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Fasciculations are characteristic features of amyotrophic lateral sclerosis (ALS), and suggest motor nerve hyperexcitability. Recent reports have shown that an increase in persistent nodal sodium current is associated with shorter survival in ALS patients. This objective of this trial is to study the efficacy and safety of mexiletine, a sodium channel blocker, for ALS. Sixty eligible participants were randomly allocated (1:1) to riluzole 100 mg or riluzole plus mexiletine 300 mg. The primary endpoint was change in the revised ALS functional rating scale (ALSFRS-R) scores during six months. We also monitored strength-duration time constant (SDTC, a measure of persistent sodium current) in median motor axons. Results showed that during six months of treatment, changes in the ALSFRS-R score and SDTC were -7.0 ± 7.1 and -0.04 ± 0.1, respectively, in the riluzole group and -6.9 ± 6.4 and 0.04 ± 0.1, respectively, in the mexiletine group (p = 0.96 and 0.049). Adverse events amounted 20% in the riluzole and 33% in the mexiletine groups. In conclusion, the results suggest that daily 300 mg mexiletine has no effects on axonal sodium current and ALSFRS-R deterioration in ALS. We have to attempt another trial using a higher dose of mexiletine or other agents to suppress sodium currents and ALS progression in the future.

Original languageEnglish
Pages (from-to)353-358
Number of pages6
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume16
Issue number5-6
DOIs
Publication statusPublished - 2015 Aug 27
Externally publishedYes

Fingerprint

Sodium Channel Blockers
Mexiletine
Amyotrophic Lateral Sclerosis
Riluzole
Randomized Controlled Trials
Safety
Sodium
Fasciculation
Axons
Survival

Keywords

  • amyotrophic lateral sclerosis
  • clinical trial
  • Mexiletine
  • nerve excitability
  • sodium current

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis : Efficacy and safety of sodium channel blocker phase II trial. / Shibuya, Kazumoto; Misawa, Sonoko; Kimura, Hideki; Noto, Yu Ichi; Sato, Yasunori; Sekiguchi, Yukari; Iwai, Yuta; Mitsuma, Satsuki; Beppu, Minako; Watanabe, Keisuke; Fujimaki, Yumi; Tsuji, Yukiko; Shimizu, Toshio; Mizuno, Toshiki; Nakagawa, Masanori; Sawaguchi, Kyoko; Hanaoka, Hideki; Kuwabara, Satoshi.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 16, No. 5-6, 27.08.2015, p. 353-358.

Research output: Contribution to journalArticle

Shibuya, K, Misawa, S, Kimura, H, Noto, YI, Sato, Y, Sekiguchi, Y, Iwai, Y, Mitsuma, S, Beppu, M, Watanabe, K, Fujimaki, Y, Tsuji, Y, Shimizu, T, Mizuno, T, Nakagawa, M, Sawaguchi, K, Hanaoka, H & Kuwabara, S 2015, 'A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 16, no. 5-6, pp. 353-358. https://doi.org/10.3109/21678421.2015.1038277
Shibuya, Kazumoto ; Misawa, Sonoko ; Kimura, Hideki ; Noto, Yu Ichi ; Sato, Yasunori ; Sekiguchi, Yukari ; Iwai, Yuta ; Mitsuma, Satsuki ; Beppu, Minako ; Watanabe, Keisuke ; Fujimaki, Yumi ; Tsuji, Yukiko ; Shimizu, Toshio ; Mizuno, Toshiki ; Nakagawa, Masanori ; Sawaguchi, Kyoko ; Hanaoka, Hideki ; Kuwabara, Satoshi. / A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis : Efficacy and safety of sodium channel blocker phase II trial. In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2015 ; Vol. 16, No. 5-6. pp. 353-358.
@article{620401f84f034acb9f13a923eba97c72,
title = "A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial",
abstract = "Fasciculations are characteristic features of amyotrophic lateral sclerosis (ALS), and suggest motor nerve hyperexcitability. Recent reports have shown that an increase in persistent nodal sodium current is associated with shorter survival in ALS patients. This objective of this trial is to study the efficacy and safety of mexiletine, a sodium channel blocker, for ALS. Sixty eligible participants were randomly allocated (1:1) to riluzole 100 mg or riluzole plus mexiletine 300 mg. The primary endpoint was change in the revised ALS functional rating scale (ALSFRS-R) scores during six months. We also monitored strength-duration time constant (SDTC, a measure of persistent sodium current) in median motor axons. Results showed that during six months of treatment, changes in the ALSFRS-R score and SDTC were -7.0 ± 7.1 and -0.04 ± 0.1, respectively, in the riluzole group and -6.9 ± 6.4 and 0.04 ± 0.1, respectively, in the mexiletine group (p = 0.96 and 0.049). Adverse events amounted 20{\%} in the riluzole and 33{\%} in the mexiletine groups. In conclusion, the results suggest that daily 300 mg mexiletine has no effects on axonal sodium current and ALSFRS-R deterioration in ALS. We have to attempt another trial using a higher dose of mexiletine or other agents to suppress sodium currents and ALS progression in the future.",
keywords = "amyotrophic lateral sclerosis, clinical trial, Mexiletine, nerve excitability, sodium current",
author = "Kazumoto Shibuya and Sonoko Misawa and Hideki Kimura and Noto, {Yu Ichi} and Yasunori Sato and Yukari Sekiguchi and Yuta Iwai and Satsuki Mitsuma and Minako Beppu and Keisuke Watanabe and Yumi Fujimaki and Yukiko Tsuji and Toshio Shimizu and Toshiki Mizuno and Masanori Nakagawa and Kyoko Sawaguchi and Hideki Hanaoka and Satoshi Kuwabara",
year = "2015",
month = "8",
day = "27",
doi = "10.3109/21678421.2015.1038277",
language = "English",
volume = "16",
pages = "353--358",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis

T2 - Efficacy and safety of sodium channel blocker phase II trial

AU - Shibuya, Kazumoto

AU - Misawa, Sonoko

AU - Kimura, Hideki

AU - Noto, Yu Ichi

AU - Sato, Yasunori

AU - Sekiguchi, Yukari

AU - Iwai, Yuta

AU - Mitsuma, Satsuki

AU - Beppu, Minako

AU - Watanabe, Keisuke

AU - Fujimaki, Yumi

AU - Tsuji, Yukiko

AU - Shimizu, Toshio

AU - Mizuno, Toshiki

AU - Nakagawa, Masanori

AU - Sawaguchi, Kyoko

AU - Hanaoka, Hideki

AU - Kuwabara, Satoshi

PY - 2015/8/27

Y1 - 2015/8/27

N2 - Fasciculations are characteristic features of amyotrophic lateral sclerosis (ALS), and suggest motor nerve hyperexcitability. Recent reports have shown that an increase in persistent nodal sodium current is associated with shorter survival in ALS patients. This objective of this trial is to study the efficacy and safety of mexiletine, a sodium channel blocker, for ALS. Sixty eligible participants were randomly allocated (1:1) to riluzole 100 mg or riluzole plus mexiletine 300 mg. The primary endpoint was change in the revised ALS functional rating scale (ALSFRS-R) scores during six months. We also monitored strength-duration time constant (SDTC, a measure of persistent sodium current) in median motor axons. Results showed that during six months of treatment, changes in the ALSFRS-R score and SDTC were -7.0 ± 7.1 and -0.04 ± 0.1, respectively, in the riluzole group and -6.9 ± 6.4 and 0.04 ± 0.1, respectively, in the mexiletine group (p = 0.96 and 0.049). Adverse events amounted 20% in the riluzole and 33% in the mexiletine groups. In conclusion, the results suggest that daily 300 mg mexiletine has no effects on axonal sodium current and ALSFRS-R deterioration in ALS. We have to attempt another trial using a higher dose of mexiletine or other agents to suppress sodium currents and ALS progression in the future.

AB - Fasciculations are characteristic features of amyotrophic lateral sclerosis (ALS), and suggest motor nerve hyperexcitability. Recent reports have shown that an increase in persistent nodal sodium current is associated with shorter survival in ALS patients. This objective of this trial is to study the efficacy and safety of mexiletine, a sodium channel blocker, for ALS. Sixty eligible participants were randomly allocated (1:1) to riluzole 100 mg or riluzole plus mexiletine 300 mg. The primary endpoint was change in the revised ALS functional rating scale (ALSFRS-R) scores during six months. We also monitored strength-duration time constant (SDTC, a measure of persistent sodium current) in median motor axons. Results showed that during six months of treatment, changes in the ALSFRS-R score and SDTC were -7.0 ± 7.1 and -0.04 ± 0.1, respectively, in the riluzole group and -6.9 ± 6.4 and 0.04 ± 0.1, respectively, in the mexiletine group (p = 0.96 and 0.049). Adverse events amounted 20% in the riluzole and 33% in the mexiletine groups. In conclusion, the results suggest that daily 300 mg mexiletine has no effects on axonal sodium current and ALSFRS-R deterioration in ALS. We have to attempt another trial using a higher dose of mexiletine or other agents to suppress sodium currents and ALS progression in the future.

KW - amyotrophic lateral sclerosis

KW - clinical trial

KW - Mexiletine

KW - nerve excitability

KW - sodium current

UR - http://www.scopus.com/inward/record.url?scp=84945114875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945114875&partnerID=8YFLogxK

U2 - 10.3109/21678421.2015.1038277

DO - 10.3109/21678421.2015.1038277

M3 - Article

C2 - 25960085

AN - SCOPUS:84945114875

VL - 16

SP - 353

EP - 358

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 5-6

ER -